Claims for Patent: 8,778,305

Summary for Patent: 8,778,305

Title:	PSMA-binding agents and uses thereof
Abstract:	Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Inventor(s):	Pomper; Martin (Baltimore, MD), Mease; Ronnie Charles (Fairfax, VA), Chen; Ying (Timonium, MD)
Assignee:	The Johns Hopkins University (Baltimore, MD)
Application Number:	13/057,044
Patent Claims:	1. A compound having the structure ##STR00036## Wherein Z is tetrazole or CO.sub.2Q; each Q is independently selected from hydrogen or a protecting group; and wherein (A) m is 0, 1, 2, 3, 4, 5, or 6; R is a pyridine ring selected from the group consisting of ##STR00037## wherein X is fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, chlorine, bromine, a radioisotope of bromine, a radioisotope of astatine, NO.sub.2, NH.sub.2, N.sup.+(R.sup.2).sub.3, Sn(R.sup.2).sub.3, Si(R.sup.2).sub.3, Hg(R.sup.2), B(OH).sub.2, --NHNH.sub.2, --NHN.dbd.CHR.sup.3, --NHNH--CH.sub.2R.sup.3; n is 1, 2, 3, 4, or 5; Y is O, S, N(R'), C(O), NR'C(O), C(O)N(R'), OC(O), C(O)O, NR'C(O)NR', NR'C(S)NR', NR'S(O).sub.2, S(CH.sub.2).sub.p, NR'(CH.sub.2).sub.p, O(CH.sub.2).sub.p, OC(O)CHR.sup.8NHC(O), NHC(O)CHR.sup.8NHC(O), or a covalent bond; wherein p is 1, 2, or 3, R' is H or C.sub.1-C.sub.6 alkyl, and R.sup.8 is hydrogen, alkyl, aryl or heteroaryl, each of which may be substituted; R.sup.2 is C.sub.1-C.sub.6 alkyl; and R.sub.3 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl each of which is substituted by fluorine, iodine, a radioisotope of fluorine, a radioisotope of iodine, chlorine, bromine, a radioisotope of bromine, or a radioisotope of astatine, NO.sub.2, NH.sub.2, N.sup.+(R.sup.2).sub.3, Sn(R.sup.2).sub.3, Si(R.sup.2).sub.3, Hg(R.sup.2), or B(OH).sub.2. 2. A compound according to claim 1, wherein Z is CO.sub.2Q. 3. A compound according to claim 1, wherein Q is hydrogen. 4. A compound according to claim 1, where m is 1, 2, 3, or 4. 5. A compound according to claim 1, having the structure ##STR00038## wherein m is not 0. 6. A compound according to claim 5, where Z is CO.sub.2Q, Q is hydrogen, and m is 4. 7. A compound according to claim 1, having the structure ##STR00039## wherein m is not 0. 8. A compound according to claim 7, where Z is CO.sub.2Q, Q is hydrogen, and m is 1, 2, or 3. 9. A compound according to claim 1, wherein n is 1. 10. A compound according to claim 1, wherein X or X' is fluorine, iodine, or a radioisotope of fluorine or iodine, bromine, a radioisotope of bromine, or a radioisotope of astatine. 11. A compound according to claim 1, wherein X or X' is fluorine, iodine, or a radioisotope of fluorine or iodine. 12. A compound according to claim 1, wherein R comprises a radioisotope. 13. A compound according to claim 12, wherein the radioisotope is selected from the group consisting of .sup.18F, .sup.123I, .sup.124I, .sup.125I, .sup.126I, .sup.131I, .sup.75Br, .sup.76Br, .sup.77Br, .sup.80Br, .sup.80mBr, .sup.82Br, .sup.83Br and .sup.211At. 14. A method of imaging one or more cells, organs or tissues comprising exposing the cell to or administering to a organism an effective amount of a compound according to claim 12. 15. The method according to claim 14, wherein the one or more organs or tissues includes prostate tissue, kidney tissue, brain tissue vascular tissue or tumor tissue. 16. A compound according to claim 1 selected from the group consisting of ##STR00040## ##STR00041## 17. A method of treating a tumor comprising administering a therapeutically effective amount of a compound according to claim 1 comprising a therapeutically effective radioisotope. 18. A kit comprising a compound according to claim 1.